Oncology and Hematology - Global Oncology Academy

225-240 of 663

MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
Luis Paz-Ares, MD, PhD; Lauren A. Byers, MD
0.50 credits 6 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 6 episodes
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Luis Paz-Ares, MD, PhD; Lauren A. Byers, MD
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
MinuteCE®
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Luis Paz-Ares, MD, PhD
0.50 program credits
- Luis Paz-Ares, MD, PhD
0.50 program credits
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Luis Paz-Ares, MD, PhD; Lauren A. Byers, MD
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Lauren A. Byers, MD
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Charles Turck, PharmD, BCPS, BCCCP; Jonathon B. Cohen, MD, MS
- Charles Turck, PharmD, BCPS, BCCCP
- Jonathon B. Cohen, MD, MS
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Hallie Blevins, PhD
- Hallie Blevins, PhD
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Global Oncology Academy
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Gerard A. Silvestri MD, MS, Master FCCP; Jessica S. Donington, MD, MSCR
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Global Oncology Academy
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Gerard A. Silvestri MD, MS, Master FCCP; Jessica S. Donington, MD, MSCR
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Ryan Quigley
- Ryan Quigley
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Marlene Mimi Maeusli, PhD.
- Marlene Mimi Maeusli, PhD.
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Project Oncology®
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Paola Marignani, PhD, EMBA
- Paola Marignani, PhD, EMBA
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Project Oncology®
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Charles Turck, PharmD, BCPS, BCCCP; Samuel Yamshon, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Yamshon, MD
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
Project Oncology®
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
Charles Turck, PharmD, BCPS, BCCCP; Sairah Ahmed, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Project Oncology®
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
John Cho, MD, PhD, FRCPC
- John Cho, MD, PhD, FRCPC
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Project Oncology®
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
John Cho, MD, PhD, FRCPC
- John Cho, MD, PhD, FRCPC

15/11